Alex Hogan/STAT

MAHA’s European food envy is full of contradictions

MAHA leaders praise Europe’s food rules — but skip its sugar taxes, food labels, and health care. Can selective emulation fix U.S. chronic disease?

By Sarah Todd

STAT+ | FDA publishes rejection letters sent to drugmakers, with a big caveat

FDA's Marty Makary says release of rejection letters will help drugmakers and investors understand decisions behind denials. But there's a big caveat.

By Andrew Joseph and Lizzy Lawrence

FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility

The shot, called Spikevax, is cleared for kids who have at least one condition putting them at increased risk.

By Helen Branswell

Adobe

STAT+ | How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition

The battle over Eylea has focused interest on a pair of congressional bills that attempt to address how drug companies exploit the U.S. patent system.

By Ed Silverman

STAT+ | Renasant Bio, an underdog in the race to develop kidney disease therapies, raises $54.5 million

The company plans to develop two therapies for a common renal condition called autosomal dominant polycystic kidney disease, or ADPKD.

By Allison DeAngelis

STAT+ | Opinion: How to evaluate GLP-1s and Medicare costs? Here’s one idea

CMS should create a new value-based care payment pilot that would test coverage of GLP-1s on beneficiaries.

By Soumi Saha and Somaieh McMullan

NIH grant cuts, FDA transparency questions, and biotech M&A

In this week's episode, a closer look at the NIH’s grant-cutting legal playbook and a not-so-transparent transparency push by the FDA chief.

By Adam Feuerstein, Allison DeAngelis, and Elaine Chen

STAT+ | Eyes on Soleno’s Prader-Willi drug launch

In this week's edition of "Adam's Biotech Scorecard," Adam also hears a a Cogent-Blueprint analysis that favors the bears.

By Adam Feuerstein